Merged Dow-Olin Names New Executives

Dow Chemical and Olin Corporation completed their chlor-alkali, chlorinated organics and epoxy asset merger at the beginning of the third quarter and have appointed new executives to the combined company that will operate under the Olin umbrella.

The two new directors, designated by Dow in connection with the Reverse Morris Trust transaction, are William H. Weideman and Carol A. Williams.

During his 38 years at Dow, Weideman, 61, served in senior financial and management roles across Dow's portfolio of businesses and in his last position was chief financial officer and executive vice president from March 2010 to January 2015. He is also on the board of directors of Sadara Chemical Company, the joint venture with SABIC.

Williams, 57, served as a special advisor to the Dow CEO Andrew Liveris until early 2015. Prior to this, she was the chemical giant’s executive vice president of manufacturing and engineering, supply chain and environmental, health & safety operations. In an earlier position she was vice president for the North American chlor-alkali business.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.